Frequency of patient-provider conversations and patient activation are the 2 most significant predictors of a high-risk patient’s behaviors to prevent kidney disease. Objectives: In the US, an ...
Neonatal Respiratory Distress Syndrome (RDS) occurs in preterm infants, due to structural immaturity of the lungs and immaturity of the pulmonary surfactant metabolism, resulting in surfactant ...
Frequency Therapeutics successfully completed a first-in-human study evaluating its lead Progenitor Cell Activation (PCA™) candidate FX-322, which is in development to restore hearing in patients with ...
Lung cancer is the most common cause of cancer mortality worldwide. Non-small-cell lung carcinomas (NSCLCs), which represent around 80% of lung tumors, exhibit poor prognosis and are usually ...
WOBURN, Mass.--(BUSINESS WIRE)--Frequency Therapeutics, a clinical-stage biotechnology company focused on harnessing the body’s innate biology to repair or reverse damage caused by a broad range of ...